| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1293 | 2019 |
| Effect of early treatment with ivermectin among patients with Covid-19 G Reis, EASM Silva, DCM Silva, L Thabane, AC Milagres, TS Ferreira, ... New England Journal of Medicine 386 (18), 1721-1731, 2022 | 219 | 2022 |
| Early treatment with pegylated interferon lambda for Covid-19 G Reis, EAS Moreira Silva, DC Medeiros Silva, L Thabane, VHS Campos, ... New England Journal of Medicine 388 (6), 518-528, 2023 | 119 | 2023 |
| Interferon treatments for SARS-CoV-2: challenges and opportunities D Jhuti, A Rawat, CM Guo, LA Wilson, EJ Mills, JI Forrest Infectious Diseases and Therapy 11 (3), 953-972, 2022 | 28 | 2022 |
| Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: a randomized platform trial G Reis, EA dos Santos Moreira Silva, DC Medeiros Silva, L Thabane, ... Annals of internal medicine 176 (5), 667-675, 2023 | 26 | 2023 |
| Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials CM Guo, O Harari, C Chernecki, K Thorlund, JI Forrest The American Journal of Tropical Medicine and Hygiene 106 (5), 1315, 2022 | 19 | 2022 |
| Survival in early phase immuno-oncology trials: development and validation of a prognostic index D Day, C Guo, Y Kanjanapan, B Tran, A Spreafico, AM Joshua, L Wang, ... JNCI Cancer Spectrum 3 (4), pkz071, 2019 | 6 | 2019 |
| Early treatment with fluvoxamine among patients with COVID-19: a cost-consequence model FP Mills, G Reis, LA Wilson, K Thorlund, JI Forrest, CM Guo, DR Boulware, ... The American Journal of Tropical Medicine and Hygiene 108 (1), 101, 2023 | 5 | 2023 |
| Effectiveness of early-treatment interventions on self-reported long COVID: A multi-arm, multi-stage adaptive platform control trial G Reis, L Wilson, D Ayers, E Silva, D Medeiros, L Thabane, V Campos, ... | 1 | 2023 |
| Resilient clinical trial infrastructure in response to the COVID-19 pandemic: lessons learned from the TOGETHER randomized platform clinical trial JI Forrest, A Rawat, F Duailibe, CM Guo, S Sprague, P McKay, G Reis, ... The American Journal of Tropical Medicine and Hygiene 106 (2), 389, 2022 | 1 | 2022 |
| Changing trends in phase 1 oncology clinical trials R Kelly, C Guo, J Desai, B Tran Contemporary Clinical Trials Communications 37, 101239, 2024 | | 2024 |
| The value of networks in driving phase I trials: the Peter MacCallum Cancer Centre experience J Desai, C Guo, B Tran Chinese Clinical Oncology 8 (3), 23-23, 2019 | | 2019 |
| Early Treatment with Fluvoxamine Among Patients with COVID-19: A Cost-Consequence Model G Reis, JI Forrest, CM Guo, EJ Mills | | |
